Trial Profile
A Study to Evaluate the Safety and Maximum Tolerated Dose (MTD) of Sorafenib and Bevacizumab Combination in Patients with Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 24 Dec 2015 New trial record